Internship

Regulatory Co-Op

Posted on 9/30/2024

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Cambridge, MA, USA

Hybrid working environment.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • Pursuing a bachelor’s degree in a medical or scientific field.
  • Demonstrated ability to analyze and present strategy, either through coursework or leadership position in a student or civic organization.
  • A team player who is curious, motivated to learn, organized, and has excellent communication skills.
Responsibilities
  • Assist the regulatory strategy leads in setting, supporting, and executing regulatory activities.
  • Support improvement and implementation of regulatory processes including chronology logs, trackers, and research regulatory precedent and competitive intelligence.
  • Participate in cross-functional meetings and discussions as appropriate.
  • Learn about and support other regulatory functions including CMC, Operations, and Labeling.

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures rather than temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Beam Therapeutics distinguishes itself from competitors by its commitment to rigorous scientific development and a values-driven approach, emphasizing the importance of its expert team. The ultimate goal is to advance genetic medicine to offer lasting cures for patients.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

3%

1 year growth

1%

2 year growth

-5%
Simplify Jobs

Simplify's Take

What believers are saying

  • Growing interest in base editing positions Beam as a leader in genetic correction.
  • Partnerships with companies like Eli Lilly enhance financial stability and research expansion.
  • Base editing's potential to treat various genetic disorders opens new markets for Beam.

What critics are saying

  • Competition from CRISPR Therapeutics could impact Beam's market share.
  • Recent restructuring and layoffs may cause operational challenges and R&D delays.
  • New CFO transition might lead to financial management challenges.

What makes Beam Therapeutics unique

  • Beam Therapeutics uses base editing, a precise genetic correction method.
  • The company focuses on lifelong cures for genetic disorders, not just symptom management.
  • Beam's partnerships with major pharmaceutical companies enhance its research capabilities.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE